The iR(2) regimen(ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma
Authors
Ramchandren, RJohnson, P
Ghosh, N
Ruan, J
Ardeshna, M
Johnson, R
Verhoef, G
Cunningham, D
de Vos, S
Kassam, S
Fayad, L
Radford, John A
Bailly, S
Offner, F
Morgan, D
Munoz, J
Ping, J
Co, M
Neuenburg, K
Goy, A
Affiliation
Case Western Reserve University (CWRU) - University Hospitals Cleveland Medical Center, Cleveland, OHIssue Date
2018
Metadata
Show full item recordCitation
Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna K, Johnson R, et al. The iR(2) regimen(ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed/refractory non-germinal center-like diffuse large B-cell lymphoma. Blood. 2018;132.Journal
BloodDOI
10.1182/blood-2018-99-111163Additional Links
https://dx.doi.org/10.1182/blood-2018-99-111163Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-99-111163